BridgeMD
Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies
EU CTIS ID: 2022-501648-14-00
What this study is testing
To evaluate long-term safety after treatment with Miltenyi CAR T cell therapy
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient underwent treatment with a Miltenyi CAR T cell therapy at least 12 months prior to enrollment in long-term follow-up
- Patient has provided informed consent prior to enrollment
You likely can't join if
- No exclusion criteria are defined for this long-term follow-up trial
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 0-17 years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.